Skip to main contentAI and Advanced
/
SHILPAMED · NSEBSE SENSEX74,336.45+0.45%BSE |
NIFTY 5023,217.6+0.43%NSE |
NIFTY BANK56,292.45+0.89%NSE |
NIFTY IT29,087.65-1.58%NSE |
NIFTY AUTO26,893.65+0.51%NSE |
NIFTY FMCG45,559+1.63%NSE |
NIFTY PHARMA26,146.2-0.16%NSE |
NIFTY 50022,532+0.24%NSE |
SH
NSE · Equity shares · Biotechnology & Drugs16.15 · 1.77%
Shilpa Medicare SHILPAMED
NSE:INR 928.05
BSE:INR 933.2
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
AI analysis and Advanced tools for SHILPAMED
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 911.9
Day rangeINR 874.85 — INR 945
52-week rangeINR 259.5 — INR 980.1
Volume11.83 L
Market cap14,474.03
P/E27.87
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)1,538.87
Net Income (INR Cr)243.33
Rev Growth (5 Year %)11.3
EPS Growth (5 Year %)6.54
P/E Ratio27.87
Book Value96.95
EPS13.49
Price/BV9.57Computed
Research path: Interpret Shilpa Medicare's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
SHILPAMEDShilpa Medicare1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 3,705.61 | 3,310.71 | 3,093.24 |
| Cash Equivalents | 45.18 | 0.67 | 7.28 |
| Other Liabilities Total | 81.22 | 39.57 | 38.27 |
| Long Term Debt | 183.81 | 231.96 | 560.16 |
| Common Stock Total | 19.56 | 9.78 | 8.68 |
| Other Current Assets Total | 124.45 | 3.83 | 2.81 |
| Total Assets | 3,705.61 | 3,310.71 | 3,093.24 |
| Current Portof LT Debt/Capital Leases | 474.73 | 47.74 | 15.23 |
| Total Equity | 2,591.2 | 2,372.24 | 1,808.69 |
| Long Term Investments | 65.24 | 34.73 | 40.29 |
| Retained Earnings(Accumulated Deficit) | 2,571.64 | 1,163.92 | 1,085.62 |
| Total Common Shares Outstanding | 19.56 | 19.56 | 17.36 |
| Tangible Book Valueper Share Common Eq | 96.95 | 92.42 | 74.95 |
| Goodwill Net | 46.86 | 46.23 | 46.23 |
| Total Liabilities | 1,114.41 | 938.47 | 1,284.55 |
| Total Debt | 659.86 | 587.75 | 937.39 |
| Short Term Investments | 46.51 | Not available | Not available |
| Cashand Short Term Investments | 91.69 | 25.97 | 30.23 |
| Total Receivables Net | 526.84 | 567.64 | 468.56 |
| Accounts Receivable-Trade Net | 518.85 | 469.88 | 392.18 |
| Property/Plant/Equipment Total-Net | 1,782.1 | 1,674.96 | 1,596.19 |
| Minority Interest | 0 | -8.54 | -8.74 |
| Total Current Liabilities | 848.06 | 674.23 | 693.59 |
| Total Inventory | 366.79 | 372.65 | 359.49 |
| Accounts Payable | 142.47 | 95.38 | 174.15 |
| Other Currentliabilities Total | 230.86 | 191.36 | 108.95 |
| Total Long Term Debt | 185.13 | 233.21 | 561.43 |
| Intangibles Net | 648.21 | 518.42 | 461.22 |
| Other Long Term Assets Total | 53.43 | 20.22 | 30.76 |
| Total Current Assets | 1,109.77 | 985.67 | 876.24 |
| Capital Lease Obligations | 1.32 | 1.25 | 1.27 |
| Accumulated Depreciation Total | Not available | -585.02 | -506.87 |
| Accrued Expenses | Not available | 32.95 | 34.53 |
| Other Equity Total | Not available | -14.41 | -10.56 |
| Prepaid Expenses | Not available | 15.58 | 15.15 |
| Additional Paid-In Capital | Not available | 1,212.96 | 724.95 |
| Cash | Not available | 25.3 | 22.95 |
| Property/Plant/Equipment Total-Gross | Not available | 1,797.45 | 1,700.06 |
| Notes Payable/Short Term Debt | Not available | 306.81 | 360.73 |
| Note Receivable-Long Term | Not available | 30.48 | 42.31 |
Fundamentals
Valuation and ratios
Valuation
PEG Ratio8.82
Price to Sale Ratio9.41
Growth
Debt 5Yr CAGR %-4.85
Margins
Operating Margin 12m18.81
Operating Margin 5y Avg11.46
Net Profit Margin 12m15.82
Net Profit Margin 5y6.21
Yield
Dividend Yield %0.08
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskBalanced risk
Board Risk44.77
Analyst consensus
ConsensusBuy
Consensus score2.00
Analyst opinions3
Strong Sell count0
Sell count0
Hold count1
Buy count1
Strong Buy count1
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Sun Pharmaceutical Industries | INR 1,944 | 4.66 L | 38.4 | — |
| Divi's Laboratories | INR 8,291.55 | 2.20 L | 73.32 | — |
| Torrent Pharmaceuticals | INR 4,965 | 1.89 L | 72.73 | — |
| Cipla | INR 1,475 | 1.19 L | 27.57 | — |
| Zydus Lifesciences | INR 1,106.25 | 1.10 L | 21.19 | — |
Shareholding
Ownership
- Promoter
- 40.13%
- FII
- 11.39%
- MF
- 4.21%
- Other
- 44.27%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Sumeet Bagadia recommends these five breakout stocks to buy today — 10 July 2026Market news · 10 Jul 2026, 7:41 am
Sumeet Bagadia recommends these five breakout stocks to buy today — Ujjivan Small Finance Bank, Bajaj Consumer Care, Shilpa Medicare, Anant Raj, and Manorama Industries
Rajesh Palviya of Axis Sec suggests Voltamp Transformers, Shilpa Medicare, Persistent Systems shares to buy on April 6Market news · 3 Apr 2026, 9:55 am
The domestic equity markets are closed on Good Friday. On April 2, Nifty 50 rose 0.15% and Sensex 0.25% despite ongoing market challenges due to the Iran conflict and rising crude prices. India's manufacturing sector slowed, raising concerns over growth and inflation.
Tata Investment, Shilpa Medicare to Julien Agro: 9 stocks to watch for stock split, bonus issue in OctoberMarket news · 26 Sept 2025, 4:44 pm
Nine stocks are set to undergo stock splits or issue bonus shares in the upcoming month of October, following recent corporate announcements.
Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy today — 14 August 2025Market news · 14 Aug 2025, 7:01 am
Sumeet Bagadia recommends five breakout stocks to buy today: Gujarat Apollo Industries, Vimta Labs, Skipper Ltd (India), Indian Metals and Ferro Alloys, and Shilpa Medicare.
Reliance Infra, Va Tech Wabag among 18 micro-cap stocks that surged up to 24% in a week amid stock market volatilityMarket news · 28 May 2025, 2:10 pm
Amid market fluctuations, microcap stocks such as Shilpa Medicare and Va Tech Wabag achieved significant gains. The Nifty Microcap 250 index outperformed the Nifty 50, rising 2.33% over the past week, with Dishman Carbogen Amics, Reliance Infra emerging as top gainers.
Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy today — 23 May 2025Market news · 23 May 2025, 6:30 am
Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy today — Shilpa Medicare, Surya Roshni, Finolex Industries, Clean Science and Technology, and Mahindra Lifespace Developers.
Corporate actions
Events
- dividendRs.0.6000 per share(60%)Final Dividend
- board MeetingsQuarterly Results
- annual General MeetingPOM
- board MeetingsAudited Results & Dividend
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- annual General MeetingPOM
- bonusBonus issue of equity shares in the ratio of 1:1 of Re. 1/-. (RD date revised)
Rusaka Markets Community
Discussion and sentiment for Shilpa Medicare
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Checking your Rusaka Markets account…
Company profile
Business information
What the company does
Shilpa Medicare Limited is an India-based pharmaceutical company. The Company is engaged in the manufacturing of active pharmaceutical ingredients (APIs), formulation and development service. It is engaged in APIs, intermediates, formulations, new drug delivery systems, peptides / biotech products and specialty chemicals, and others. The Company supplies more than 30 oncology APIs including key products such as Capecitabine, Gemcitabine Hydrochloride, Pemetrexed, Axitinib, Erlotinib Hydrochloride and Irinotecan Hydrochloride for various international markets including United States of America, Europe, Japan, South Korea, Russia, Mexico, Brazil, and other emerging markets. Its non-Oncology API products include Ambroxol (Mucolytic agent), Tranexmic Acid and Ursodeoxycholic Acid. Its Injectable Dosage Forms include Myelodysplastic Syndrome, Breast Cancer, Multiple Myeloma, and more. Its Oral Solid Dosage Forms include Psoriasis, Prostate Cancer, Multiple Sclerosis, and others.
Company facts
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- NSE Code
- SHILPAMED
- BSE Code
- 530549
Questions
Stock FAQ
What is the symbol and ISIN of Shilpa Medicare?
Shilpa Medicare has the symbol SHILPAMED and ISIN - INE790G01031.
What is the current price of Shilpa Medicare?
Shilpa Medicare is currently trading at INR 928.05.
What are the year high and year low of Shilpa Medicare?
Shilpa Medicare has a year high of INR 980.10 and a year low of INR 259.50.
What is the market capitalization of Shilpa Medicare?
Shilpa Medicare has a market capitalization of INR 14,474.03 crore.
What is the P/E ratio of Shilpa Medicare?
Shilpa Medicare has a P/E ratio of 27.87.
What is the dividend yield of Shilpa Medicare?
Shilpa Medicare has a dividend yield of 0.08%.
How is the financial performance of Shilpa Medicare based on revenue, net income, and EPS?
Shilpa Medicare has revenue of INR 1,538.87 crore, net income of INR 243.33 crore, and EPS of INR 13.57.
What is the book value of Shilpa Medicare?
Shilpa Medicare has a book value of INR 96.95.
What is the debt-to-equity ratio of Shilpa Medicare?
Shilpa Medicare has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Shilpa Medicare?
Shilpa Medicare has a price-to-book ratio of 9.57 and a price-to-sales ratio of 9.41.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.